OncoHelix is a global leader in advanced molecular and immune diagnostics, focusing on precision oncology, wellness, and reproductive health testing. Based in Calgary, Canada, the company collaborates with academic institutions and healthcare organizations worldwide to provide innovative diagnostic solutions.

The company offers a range of services, including clinically validated genomic profiling panels for tumors, liquid biopsy solutions for non-invasive detection of circulating tumor DNA, and immune profiling for personalized treatment insights. OncoHelix also supports translational research through biomarker discovery and custom genomic panel development for pharmaceutical and biotech partners. Their technology emphasizes fast turnaround times and scalable testing solutions, integrating AI-driven genomic data analysis to enhance precision medicine.

OncoHelix partners with various organizations, including the University of Calgary and Burjeel Holdings in Abu Dhabi, to expand its reach and impact in the MENA region. The leadership team comprises experts in molecular diagnostics and immunology, contributing to significant advancements in the field. The company’s mission is to make precision diagnostics accessible and reliable, improving diagnosis and treatment personalization for patients and clinicians globally.